Loading
companiesCompany
Cardiff Oncology
Cardiff Oncology is a San Diego biotech developing onvansertib, an oral PLK1 inhibitor that is being tested with chemotherapy and bevacizumab as first-line treatment for RAS-mutant colorectal cancer.
Also called: TrovageneCardiff Oncology, Inc.NASDAQ:CRDF
Overview
Cardiff Oncology, formerly the diagnostics company Trovagene, develops onvansertib, a selective oral inhibitor of Polo-like kinase 1 licensed from Nerviano Medical Sciences. The randomised phase 2 CRDF-004 trial combines onvansertib with FOLFIRI or FOLFOX plus bevacizumab in first-line RAS-mutant metastatic colorectal cancer, after earlier studies showed higher response rates in bevacizumab-naive patients. Onvansertib has also been studied in pancreatic cancer and small cell lung cancer.
Headquarters
San Diego, California, US
Scorecard
All companies#344of 1244 companies, score 11
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +6
0 approved, 0 in phase 3, 1 earlier, 1 targets, 10 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:CRDF
Stage
Public
Website
Phase 2Oral serine/threonine kinase inhibitor
Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer.